Literature DB >> 15549499

Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians.

Christophe Garenc1, Samuel Aubert1, Jèrôme Laroche2,3, Joël Girouard2, Marie-Claude Vohl1, Jean Bergeron1, François Rousseau2, Pierre Julien4.   

Abstract

Hypertriglyceridemia (HTG) is known as a common metabolic disorder associated with increased production, decrease catabolism and/or decreased hepatic uptake of triglyceride (TG)-rich particles. We assessed, in the Quebec City population, the allele frequency and haplotype distributions of mutations in genes related to HTG, such as the apolipoprotein E (APOE) (C112R and C158R), the apolipoprotein CIII (APOC3) (C-482T and C3238G) and the peroxisome proliferator-activated receptor alpha (PPARalpha) (L162V) genes. A total of 938 anonymous unlinked newborns from the metropolitan Quebec City area have been genotyped. Allele frequencies observed in the Quebec City population differed from known frequencies determined in other Caucasian populations. The co-transmitted allele distribution between the two-marker genotypes APOE/APOC3(C3238G) and APOC3(C-482T)/PPARalpha(L162V) presented a weak deviation from the assumption of genetic independence. Also, we observed a non-independent distribution of the T-482/G3238 allele combinations within the APOC3 gene, suggesting strong linkage disequilibrium between the C-482T and C3238G polymorphisms. Moreover, comparisons of allele frequencies observed in the population of Québec City to those obtained in other Caucasian populations suggested that the population of Québec City may be at a lower risk of developing HTG due to APOE, APOC3 and PPARalpha genetic variants. However, the strong linkage disequilibrium and the two-marker genotype distributions observed in the APOC3 gene suggest that these two variants may functionally interact in the Québec City population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549499     DOI: 10.1007/s10038-004-0208-6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  50 in total

1.  Model-free analysis and permutation tests for allelic associations.

Authors:  J H Zhao; D Curtis; P C Sham
Journal:  Hum Hered       Date:  2000 Mar-Apr       Impact factor: 0.444

2.  Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region.

Authors:  R Galetto; M Albajar; J I Polanco; M M Zakin; J C Rodríguez-Rey
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

3.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.

Authors:  Philippa J Talmud; Emma Hawe; Steve Martin; Michael Olivier; George J Miller; Edward M Rubin; Len A Pennacchio; Steve E Humphries
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

4.  PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.

Authors:  K Schoonjans; J Peinado-Onsurbe; A M Lefebvre; R A Heyman; M Briggs; S Deeb; B Staels; J Auwerx
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  Improved phenotyping of apolipoprotein E: application to population frequency distribution.

Authors:  J S Hill; P H Pritchard
Journal:  Clin Chem       Date:  1990-11       Impact factor: 8.327

6.  Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus.

Authors:  Dolores Corella; Marisa Guillén; Carmen Sáiz; Olga Portolés; Antonio Sabater; José Folch; Jose M Ordovas
Journal:  J Lipid Res       Date:  2002-03       Impact factor: 5.922

7.  Direct phenotyping of human apolipoprotein E in plasma: application to population frequency distribution in Paris (France).

Authors:  S Bailleul; R Couderc; V Landais; G Lefèvre; D Raichvarg; J Etienne
Journal:  Hum Hered       Date:  1993 May-Jun       Impact factor: 0.444

8.  Variability of the genetic contribution of Quebec population founders associated to some deleterious genes.

Authors:  E Heyer; M Tremblay
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

9.  Triglycerides: a risk factor for coronary heart disease.

Authors:  J Davignon; J S Cohn
Journal:  Atherosclerosis       Date:  1996-07       Impact factor: 5.162

10.  Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.

Authors:  W J McConathy; J C Gesquiere; H Bass; A Tartar; J C Fruchart; C S Wang
Journal:  J Lipid Res       Date:  1992-07       Impact factor: 5.922

View more
  5 in total

1.  Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels.

Authors:  Yin Ruixing; Li Yiyang; Li Meng; Li Kela; Long Xingjiang; Zhang Lin; Liu Wanying; Wu Jinzhen; Yang Dezhai; Lin Weixiong
Journal:  Lipids Health Dis       Date:  2010-08-17       Impact factor: 3.876

Review 2.  Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease?

Authors:  Raphaël Chouinard-Watkins; Mélanie Plourde
Journal:  Nutrients       Date:  2014-10-20       Impact factor: 5.717

3.  Sequence analysis and variant identification at the APOC3 gene locus indicates association of rs5218 with BMI in a sample of Kuwaiti's.

Authors:  Zainab H Malalla; Ahmad E Al-Serri; Huda M AlAskar; Wafaa Y Al-Kandari; Suzanne A Al-Bustan
Journal:  Lipids Health Dis       Date:  2019-12-19       Impact factor: 3.876

4.  Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.

Authors:  Qiao Lin; Yunpeng Cao; Jie Gao
Journal:  Drug Des Devel Ther       Date:  2015-09-29       Impact factor: 4.162

5.  Effects of Eicosapentaenoic Acid Supplementation on Lipid and Lipoprotein Profile in Hypertriglyceridemic Subjects with Different Proliferator-activated Receptor Alpha Genotypes.

Authors:  Hamideh Pishva; Parvin Mehdipour; Mohammad Reza Eshraghian; Soltan-Ali Mahboob
Journal:  Int J Prev Med       Date:  2014-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.